You may be aware of a national shortage of Pancreatic Enzyme Replacement Therapy (PERT), as described in the National Patient Safety Alert (NatPSA) of May 2024. The shortage arose from a reduction in the production of the leading brand, Creon®, due to limited availability of the active pharmaceutical ingredients and manufacturing constraints.
In December 2024, ICBs were asked to provide a mitigation plan in addition to the recommendations of the May 2024 NatPSA. The document that describes the plan for NHS Devon can be found here. A link will also be added to the Devon formulary.
The guidance describes the background to the issue and provides practical advice for prescribers, dispensers and patients.
In exceptional circumstances, where stock is not available and a patient is due to run out within the next 10 days, an unlicensed imported product, equivalent to Creon®, may be prescribed. Details on how to pharmacies can access these products in these exceptional circumstances are included in the guidance.